Physician profile

Jill Enright

Internal Medicine · Bellevue, WA

NPI 1740240340

$630.30

in general payments reported to CMS, 2019-2025

14 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $104.00 2019-2020
Janssen Pharmaceuticals, INC $89.47 2019-2020
Kowa Pharmaceuticals America, INC. $63.17 2019-2020
Teva Pharmaceuticals USA, INC. $59.32 2019
Horizon Therapeutics Plc $54.02 2019
Merck Sharp & Dohme LLC $45.66 2019
Astellas Pharma US INC $44.52 2019
Novartis Pharmaceuticals Corporation $40.36 2019-2020
Astrazeneca Pharmaceuticals LP $32.06 2019
Pfizer INC. $29.17 2019-2020
Glaxosmithkline, LLC. $19.51 2019
Novo Nordisk INC $18.80 2019
Dynavax Technologies Corporation $17.11 2019
Avanir Pharmaceuticals, INC. $13.13 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jill Enright

$630.30

in general payments reported 2019-2025

Years
2019-2020
Top company
Amgen INC.

https://glasscript.com/doctor/78688/jill-enright

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.